{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T02:54:07Z","timestamp":1685069647204},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T00:00:00Z","timestamp":1364947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40259-013-0024-7","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T07:58:32Z","timestamp":1364889512000},"page":"275-279","source":"Crossref","is-referenced-by-count":4,"title":["Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU"],"prefix":"10.1007","volume":"27","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,3]]},"reference":[{"issue":"Suppl. 4","key":"24_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","volume":"20","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):105\u20137.","journal-title":"Ann Oncol"},{"key":"24_CR2","unstructured":"National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines): chronic myelogenous leukemia version 2.2013. Fort Washington (PA): National Comprehensive Cancer Network, 2012."},{"issue":"13","key":"24_CR3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","volume":"71","author":"PL McCormack","year":"2011","unstructured":"McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71(13):1771\u201395.","journal-title":"Drugs"},{"issue":"3","key":"24_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11535870-000000000-00000","volume":"24","author":"F Condorelli","year":"2010","unstructured":"Condorelli F, Genazzani AA. Dasatinib: is it all in the dose? BioDrugs. 2010;24(3):157\u201363.","journal-title":"BioDrugs"},{"key":"24_CR5","unstructured":"Sprycel (dasatinib) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2012."},{"issue":"24","key":"24_CR6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"24_CR7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"key":"24_CR8","unstructured":"Hochhaus A, Boque C, Bradley Garelik M, et al. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up [poster no. 1537]. 17th Congress of the European Hematology Association, Amsterdam; 14\u201317 Jun 2012."},{"issue":"Suppl. 1","key":"24_CR9","first-page":"75","volume":"97","author":"J Mayer","year":"2012","unstructured":"Mayer J, Warzocha K, Huguet F, et al. Efficacy and safety of dasatinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): European subpopulation analysis of the phase 3 DASISION trial [abstract no. 0190]. Haematologica. 2012;97(Suppl. 1):75.","journal-title":"Haematologica"},{"issue":"19","key":"24_CR10","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100\u00a0mg vs imatinib 400\u00a0mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. 2012;120(19):3898\u2013905.","journal-title":"Blood"},{"issue":"2","key":"24_CR11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"NP Shah","year":"2010","unstructured":"Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100\u00a0mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232\u201340.","journal-title":"Haematologica"},{"key":"24_CR12","unstructured":"Rea D, Vellenga E, Junghanss C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib [poster no. 1430]. 17th Congress of the European Hematology Association, Amsterdam; 14\u201317 Jun 2012."},{"issue":"25","key":"24_CR13","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140\u00a0mg once daily versus 70\u00a0mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322\u20139.","journal-title":"Blood"},{"issue":"16","key":"24_CR14","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2\u00a0years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852\u201361.","journal-title":"Cancer"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-013-0024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0024-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T17:50:25Z","timestamp":1595613025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-013-0024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0024-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,3]]}}}